New Study in NEJM Highlights Potential Disease-Modifying Treatment for Dravet Syndrome
Biotechnology company Stoke Therapeutics and global neuroscience firm Biogen have announced the publication of important new research on the investigational medicine zorevunersen in the prestigious medical journal The New England Journal of Medicine. The newly published findings provide early evidence that the therapy could potentially modify the course of Dravet syndrome, a rare and severe genetic epilepsy disorder that begins in infancy.
The article includes results from two completed Phase 1/2a clinical studies along with data from their ongoing open-label extension (OLE) trials. Together, these studies suggest that treatment with zorevunersen may lead to long-lasting reductions in seizures while also improving several aspects of development, including cognition and behavior. Researchers observed that these benefits began during the initial clinical trial period and continued through three additional years of treatment in the extension studies.
Importantly, participants received the investigational therapy in addition to standard anti-seizure medications, meaning the improvements occurred alongside existing treatments rather than replacing them.
Understanding Dravet Syndrome
Dravet syndrome is classified as a severe developmental and epileptic encephalopathy (DEE). The condition typically appears in the first year of life and is marked by frequent and prolonged seizures that can become increasingly difficult to control. As children grow older, they often experience delays in cognitive development, communication, motor skills, and social functioning.
Most children with Dravet syndrome show signs of slowed or stalled neurodevelopment by around two years of age. Over time, this gap widens when compared with neurotypical children of the same age. The condition can also lead to additional challenges such as behavioral difficulties, sleep problems, and reduced quality of life for both patients and their families.
Despite advances in epilepsy treatment, no approved therapies currently address the underlying genetic cause of Dravet syndrome or alter its long-term progression. Most available treatments focus primarily on reducing seizure frequency rather than modifying the disease itself.
Encouraging Clinical Findings
According to the researchers, the clinical studies evaluated single and multiple doses of zorevunersen up to 70 mg, with the main goal of assessing safety and tolerability. Changes in major motor seizure frequency were analyzed as a secondary outcome.
Results showed substantial reductions in seizures among patients who received the treatment during the Phase 1/2a trials. These reductions were sustained during the open-label extension studies, where patients continued therapy for up to three years.
The strongest improvements were observed in patients who initially received 70 mg doses during the early clinical trial phase. In these participants, seizure reductions were particularly pronounced and remained stable throughout the longer-term treatment period.
Beyond seizure control, researchers also assessed neurodevelopment, functional abilities, and overall quality of life during the extension studies. Standard clinical evaluations indicated continued improvements in several key areas, including:
- Communication skills
- Motor development
- Social interaction
- Daily living abilities
- Overall quality of life
These findings suggest that the therapy may influence broader aspects of neurological development rather than only suppressing seizures.
Expert Perspective
The study’s corresponding author, pediatric neurologist Helen Cross, emphasized the potential significance of the findings. She explained that while seizure reduction remains a critical goal in treating Dravet syndrome, the improvements in cognition, behavior, and daily functioning observed in the study point toward something even more meaningful.
According to Cross, these outcomes raise the possibility that the therapy could alter the trajectory of the disease, potentially improving long-term outcomes for children living with the condition and easing the burden on families.
For many families affected by Dravet syndrome, even small improvements in independence or communication could make a major difference in everyday life.
Mary Anne Meskis, CEO of the Dravet Syndrome Foundation, reflected on the personal impact of the disease. She noted that despite progress in awareness and medical care, the disorder remains deeply challenging for patients and caregivers. A treatment that could help individuals perform daily tasks independently or communicate more effectively would significantly improve quality of life.
Safety Profile
Safety was a primary focus of the studies. Overall, zorevunersen was generally well tolerated among participants.
Across the trials:
- 81 patients received at least one dose of the investigational therapy.
- More than 800 doses have been administered so far.
The most frequently reported treatment-related side effect was an increase in cerebrospinal fluid (CSF) protein levels, which occurred more often during the extension studies. This effect was observed in about 44% of participants in those trials. However, researchers reported no associated clinical symptoms, and only one patient discontinued treatment because of this finding.
Most serious adverse events that occurred during the studies were determined to be unrelated to the drug. Only one patient experienced a suspected unexpected serious adverse reaction.
Source link :https://www.businesswire.com/
